Kwok et al., in 2001, reported that one of the primary targets that induces the anti-cancer activity is IκB kinase β (IKK-β) wherein both IKK-β and nuclear factor κB (NF-κB) signaling are impaired due to modified cysteine 179 [82]. This evidence concerns the gene NFKB1 and cancer.